Bifogade filer
Dicot Pharma AB Q3 2025 ENG
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Uppsala, Sweden, October 23, 2025. Dicot Pharma AB publishes its interim report for the third quarter of 2025. The report is available as an attached document and on www.dicotpharma.com. The company will present the report and results from the phase 2a study published earlier today in a webcast on Friday October 24 at 12.00 CEST, a broadcast that may also be viewed afterwards.
Third quarter, July-September 2025
- Net sales amounted to SEK 0.0 (0.0) million
- Earnings after financial items amounted to SEK -16.1 (-10.2) million
- Earnings per share amounted to SEK -0.01 (-0.01)
“As a company, we have now moved to the next level, with results qualifying us to proceed in our clinical development.”, comments Elin Trampe, CEO.
Significant events during the quarter
- When all participants had made their final clinic visit in August, the clinical part of the phase 2a study was completed.
- As of August 27, Dicot Pharma is included in the MSCI Global Micro Cap Index, which is the investment basis for index funds and institutional asset managers.
- In September, the US investment bank Oppenheimer highlights in a report the strong link between erectile dysfunction and longevity and highlights the potency drug candidate LIB-01 as particularly interesting.
Significant events after the quarter
- Topline results from the clinical phase 2a study were announced October 23 and show an improvement of erectile function at week 4, following a single 3-day oral treatment of LIB-01. Moreover, the effect was sustained at week 8. LIB-01 was well tolerated.
The interim report and the study result from phase 2a will be presented by CEO Elin Trampe, CSO Charlotta Gauffin, and CFO Björn Petersson in a live broadcast from Direkt Studio tomorrow Friday October 24 at 12.00 CEST. A link to the broadcast will be available at WEBINAR or via a link at www.dicotpharma.com. Questions can be posed prior to the meeting to info@dicotpharma.com. The broadcast may be viewed afterwards via the same link.